CHEK1 and urinary bladder cancer: Given our finding that ATR was associated with a poor prognosis and that WYC0209 can enhance cisplatin-induced DNA damage in bladder cancer cells promote us to test whether inhibition of ATR-Chk1 pathway with WYC0209 can alter cell susceptibility to cisplatin.